Caris Life Sciences (CAI) is drawing fresh attention after publishing new tumor mutational burden data, rolling out MI Clarity for breast cancer, securing MolDX approval for ChromoSeq, and reporting detailed first quarter 2026 results.

The latest run of product launches and clinical data has not yet translated into positive share price momentum, with Caris Life Sciences' share price return falling 12.35% over the past day and 45.55% year to date, suggesting sentiment has cooled despite a series of recent announcements.

If you like the healthcare and AI angle here, it could be worth scanning for other companies using similar technology by checking out 33 healthcare AI stocks

With the stock down sharply this year but trading at a sizeable discount to the current analyst price target and intrinsic value estimate, you have to ask: Is Caris Life Sciences undervalued here, or is the market already pricing in its future growth?

Most Popular Narrative: 80.2% Undervalued

Caris Life Sciences last closed at $14.69, while the most followed narrative assigns a fair value of $74.17. This creates a wide valuation gap that hinges on its data driven TechBio model.

Caris Life Sciences ($CAI) is the "Big Data" play of the biotech world. While companies like Recursion ($RXRX) use AI to find drugs, Caris uses AI to tell doctors which drug to use for a specific patient. They possess the world's largest and most comprehensive clinico-genomic database. The market currently prices CAI as a standard diagnostic lab, missing the massive optionality of its "Data-as-a-Service" business model, where pharmaceutical giants pay to access its treasure trove of patient data for drug discovery.

Want to see what supports such a big gap between price and narrative fair value? The thesis leans on rapid revenue expansion, rising margins, and a premium future earnings multiple. Curious which specific assumptions drive that $74.17 figure and how sensitive they are to growth slowing?

Result: Fair Value of $74.17 (UNDERVALUED)

However, this bullish story can crack if AI driven oncology adoption slows, or if losses of $411.424 million keep funding needs and dilution worries front and center.

Next Steps

If the optimism in this narrative feels compelling, do not let it be your only anchor. Move quickly, review the underlying numbers yourself, and weigh the 4 key rewards.

Ready for more investment ideas?

If Caris Life Sciences has your attention, do not stop here. Use the Simply Wall St screener to quickly surface other stocks that might fit your style.

• Target potential upside by scanning companies that trade at a discount and still meet quality checks using the 47 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with sturdy finances and consistent fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).
• Get a head start on lesser known opportunities by sifting through a screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.